Premium
Studies on the interaction between TWEAK and the death receptor WSL‐1/TRAMP (DR3)
Author(s) -
Kaptein Allard,
Jansen Mieke,
Dilaver Gonul,
Kitson Jeremy,
Dash Laura,
Wang Edward,
Owen Michael J,
Bodmer Jean-Luc,
Tschopp Jurg,
Farrow Stuart N
Publication year - 2000
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(00)02219-5
Subject(s) - tramp , receptor , apoptosis , tumor necrosis factor alpha , programmed cell death , microbiology and biotechnology , in vitro , ligand (biochemistry) , chemistry , biology , cancer research , biochemistry , immunology , gene , transgene
WSL‐1/TRAMP (DR3) is a member of the tumour necrosis factor (TNF) receptor superfamily which exhibits effects on NF‐κB activation and apoptosis. TWEAK, a novel TNF‐related molecule, has been proposed as the ligand for this receptor. Utilising both human and murine TWEAK ligand, it is shown that TWEAK and WSL‐1/TRAMP do not interact in an in vitro binding assay and that TWEAK binds strongly to cells that do not express WSL‐1/TRAMP on the cell surface. Biological activity of TWEAK is also observed in these cells. Finally, cells isolated from WSL‐1/TRAMP knockout mice are shown to retain their ability to interact with TWEAK. These results suggest that WSL‐1/TRAMP is not the major receptor for TWEAK